RxDoctor Payments Data

Tracy Walker, MD

Cardiovascular Disease · Emerson, NJNPI 1003836123

Payments from drug & device makers

$632in general payments, 2019–2025

Across 36 payments — averaging $17.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$137
  • Boehringer Ingelheim$119
  • Johnson & Johnson$57
  • Amarin Pharma, Inc.$56
  • Philips North America LLC$48
  • Kowa Pharmaceuticals America, Inc.$42
  • plus $173 from 9 others

What the payments were for

  • Food & beverage$632100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$632 in reported general payments places this provider in the 20th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$273,907
Medicare patients
645
Services billed
2,415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban72$105,004
EntrestoSacubitril/Valsartan31$51,860
Repatha SureclickEvolocumab15$19,178
Dabigatran EtexilateDabigatran Etexilate Mesylate14$6,288
Rosuvastatin Calcium170$2,412
Metoprolol Succinate136$2,327
Ezetimibe77$2,190
Atorvastatin Calcium111$1,339
Amlodipine Besylate152$1,101
Amiodarone Hcl18$883
Losartan Potassium75$842
ClopidogrelClopidogrel Bisulfate41$575
Diltiazem 24hr Er (Cd)Diltiazem Hcl12$570
Torsemide34$510
Valsartan22$428

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$27$51,86031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Emerson

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →